BioCryst Pharmaceuticals Inc (BCRX) – Company Profile and SWOT Analysis

BioCryst Pharmaceuticals Inc (BCRX) – Company Profile & SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Key Highlights

BioCryst Pharmaceuticals Inc (BioCryst) is a biotechnology company that designs, optimizes and develops small molecule drugs that block critical enzymes in the pathogenesis of diseases. The company focuses on the treatment of rare diseases and develops drugs for infectious diseases and hereditary angioedema. BioCryst’s products include peramivir injections, which consist of Rapivab, Alpivab, Rapiacta, Orladeyo and Peramiflu for the treatment of Influenza. The company’s other pipeline products include, BCX10013 and Avoralstat. It integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through a process known as structure-guided drug design. BioCryst is headquartered in Durham, North Carolina, the US.

Scope

• Detailed information on BioCryst Pharmaceuticals Inc required for business and competitor intelligence needs

• A study of the major internal and external factors affecting BioCryst Pharmaceuticals Inc in the form of a SWOT analysis

• An in-depth view of the business model of BioCryst Pharmaceuticals Inc including a breakdown and examination of key business segments

• News about BioCryst Pharmaceuticals Inc, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of BioCryst Pharmaceuticals Inc and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess BioCryst Pharmaceuticals Inc as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on BioCryst Pharmaceuticals Incs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

F. Hoffmann-La Roche Ltd

Daiichi Sankyo Co Ltd

Velico Medical Inc

GSK plc

Gilead Sciences Inc

Arbutus Biopharma Corp

Ionis Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

BioCryst Pharmaceuticals Inc - Key Facts

BioCryst Pharmaceuticals Inc - Key Employees

BioCryst Pharmaceuticals Inc - Key Employee Biographies

BioCryst Pharmaceuticals Inc - Major Products and Services

BioCryst Pharmaceuticals Inc - History

BioCryst Pharmaceuticals Inc - Company Statement

BioCryst Pharmaceuticals Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

BioCryst Pharmaceuticals Inc - Business Description

R&D Overview

BioCryst Pharmaceuticals Inc - Corporate Strategy

BioCryst Pharmaceuticals Inc - SWOT Analysis

SWOT Analysis - Overview

BioCryst Pharmaceuticals Inc - Strengths

BioCryst Pharmaceuticals Inc - Weaknesses

BioCryst Pharmaceuticals Inc - Opportunities

BioCryst Pharmaceuticals Inc - Threats

BioCryst Pharmaceuticals Inc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024

BioCryst Pharmaceuticals Inc, Recent Deals Summary

Section 5 – Company’s Recent Developments

Feb 26, 2024: BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones

Nov 21, 2023: Biocryst To Present at Upcoming Investor Conferences

Nov 03, 2023: BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months

Nov 02, 2023: BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update

May 03, 2023: BioCryst reports first quarter 2023 financial results and provides business update

Mar 31, 2023: BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

Feb 21, 2023: BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones

Jan 24, 2023: BioCryst and Swixx BioPharma partner for commercialisation of Orladeyo

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

BioCryst Pharmaceuticals Inc, Key Facts

BioCryst Pharmaceuticals Inc, Key Employees

BioCryst Pharmaceuticals Inc, Key Employee Biographies

BioCryst Pharmaceuticals Inc, Major Products and Services

BioCryst Pharmaceuticals Inc, History

BioCryst Pharmaceuticals Inc, Other Locations

BioCryst Pharmaceuticals Inc, Subsidiaries

BioCryst Pharmaceuticals Inc, Key Competitors

BioCryst Pharmaceuticals Inc, Ratios based on current share price

BioCryst Pharmaceuticals Inc, Annual Ratios

BioCryst Pharmaceuticals Inc, Annual Ratios (Cont…1)

BioCryst Pharmaceuticals Inc, Annual Ratios (Cont…2)

BioCryst Pharmaceuticals Inc, Interim Ratios

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024

BioCryst Pharmaceuticals Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

BioCryst Pharmaceuticals Inc, Performance Chart (2019 – 2023)

BioCryst Pharmaceuticals Inc, Ratio Charts

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports